Blog
RSS FeedPosted by Michael Wonder on 27 Jan 2022
The certainty of uncertainty in health technology assessment
26 January 2022 - History is replete with stories of poor decisions—catastrophes that leaders might have averted, and great opportunities that ...
Posted by Michael Wonder on 25 Jan 2022
ICER releases draft evidence report on novel agents to prevent chemotherapy-induced neutropenia
25 January 2022 - Registration now open for 1 February “Early Insights” webinar. Public comment period now open until 22 ...
Posted by Michael Wonder on 06 Jan 2022
ICER publishes evidence report on tirzepatide for type 2 diabetes
6 January 2022 - Tirzepatide has a novel dual GIP and GLP-1 receptor agonist mechanism of action and is seen as ...
Posted by Michael Wonder on 28 Dec 2021
ICER to assess treatments for Alzheimer’s disease
22 December 2021 - Report will be subject of CTAF meeting in July 2022; draft scoping document open to public ...
Posted by Michael Wonder on 16 Dec 2021
ICER publishes final evidence report and policy recommendations on tezepelumab for severe asthma
16 December 2021 - Independent appraisal committee found that evidence is adequate to demonstrate a net health benefit of tezepelumab ...
Posted by Michael Wonder on 02 Dec 2021
Harmonisation of health technology assessment across the European Union: lessons for the United States
2 December 2021 - In the multi-payer US system, each public program, private insurer, and self-insured employer conducts its own ...
Posted by Michael Wonder on 01 Dec 2021
ICER publishes first annual assessment of barriers to fair access within US commercial insurance prescription drug coverage
1 December 2021 - Scope of assessment limited by gaps in availability of payer policies and inability to evaluate how policies ...
Posted by Michael Wonder on 24 Nov 2021
ICER to assess gene therapy for beta thalassaemia
24 November 2021 - Report will be subject of New England CEPAC meeting in June 2022; draft scoping document open ...
Posted by Michael Wonder on 17 Nov 2021
ICER publishes final evidence report and policy recommendations on mavacamten for hypertrophic cardiomyopathy
16 November 2021 - Concerns about long-term safety influenced majority of independent appraisal committee to vote that evidence is not currently ...
Posted by Michael Wonder on 16 Nov 2021
ICER identifies most significant 2020 US drug price hikes not supported by new clinical evidence
16 November 2021 - Out of 10 identified drugs that had substantial 2020 price increases net of rebates on top of ...
Posted by Michael Wonder on 11 Nov 2021
Bolstering our ability to value health technology: a few less considered issues
9 November 2021 - Proposals for a national entity to produce and assess evidence about the relative value of medical technology ...
Posted by Michael Wonder on 09 Nov 2021
ICER releases draft evidence report on tirzepatide for type 2 diabetes mellitus
9 November 2021 - Public comment period now open until 8 December 2021; requests to make oral comment during public ...
Posted by Michael Wonder on 04 Nov 2021
ICER publishes evidence report on tezepelumab for severe asthma
4 November 2021 - Tezepelumab reduces asthma exacerbations, but there is uncertainty about long-term safety as with all new biologic ...
Posted by Michael Wonder on 20 Oct 2021
ICER publishes final evidence report and policy recommendations on therapies for myasthenia gravis
20 October 2021 - Independent appraisal committee found the evidence is adequate to demonstrate that eculizumab and efgartigimod both provide a ...
Posted by Michael Wonder on 07 Oct 2021
ICER publishes evidence report on mavacamten for hypertrophic cardiomyopathy
7 October 2021 - Evidence is rated as promising but inconclusive to determine whether mavacamten provides a net health benefit for ...